Home Featured Page 123

Featured

Latest

‘No Prejudice, No Hype’: Florence Butlen-Ducuing on Europe’s Psychedelic Renaissance

August 2025 Psychedelic Patent Update

Unpacking FDA’s MDMA Rejection Letter and the Road Ahead for Lykos

Pα+ Psychedelic Bulletin #208: Psychedelic CEOs’ FDA Wish-List; APA Division 56 President Talks Psychedelics; Compass’ PTSD Study Published; Cybin Ousts Drysdale

BREAKING: FDA Publishes Lykos Therapeutics’ MDMA Complete Response Letter (CRL)

atai Life Sciences and Massachusetts General Hospital Announce Initiation of Clinical...

FILAMENT HEALTH ANNOUNCES PSILOCYBIN SUPPLY AGREEMENT WITH THE CENTRE FOR ADDICTION...

PT374 – Personalizing Psychedelic Integration

Clearmind Medicine Announces Closing of US$7.5 Million Public Offering and Uplisting...

Psychedelic Bulletin #124: MAPS Wraps Second Phase 3 MDMA Trial; Preparing...

Why Did Psychedelics Relieve My Chronic Pain?

Psychedelics Weekly – Oregon Measure 109: Approaching the Proposed Final Rules

MAPS Wraps Second Phase 3 Trial of MDMA-Assisted Therapy for PTSD

Racing Beyond Racemic: A Look at Ketamine Drug Development Ahead of...

1...122123124...296 Page 123 of 296

EDITOR PICKS

‘No Prejudice, No Hype’: Florence Butlen-Ducuing on Europe’s Psychedelic Renaissance

August 2025 Psychedelic Patent Update

Unpacking FDA’s MDMA Rejection Letter and the Road Ahead for Lykos

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

‘No Prejudice, No Hype’: Florence Butlen-Ducuing on Europe’s Psychedelic Renaissance

August 2025 Psychedelic Patent Update

Unpacking FDA’s MDMA Rejection Letter and the Road Ahead for Lykos

Pα+ Psychedelic Bulletin #208: Psychedelic CEOs’ FDA Wish-List; APA Division 56 President Talks Psychedelics; Compass’ PTSD Study Published; Cybin Ousts Drysdale

BREAKING: FDA Publishes Lykos Therapeutics’ MDMA Complete Response Letter (CRL)

atai Life Sciences and Massachusetts General Hospital Announce Initiation of Clinical...

FILAMENT HEALTH ANNOUNCES PSILOCYBIN SUPPLY AGREEMENT WITH THE CENTRE FOR ADDICTION...

PT374 – Personalizing Psychedelic Integration

Psychedelic Brains In A Dish

Clearmind Medicine Announces Closing of US$7.5 Million Public Offering and Uplisting...

Psychedelic Bulletin #124: MAPS Wraps Second Phase 3 MDMA Trial; Preparing...

Why Did Psychedelics Relieve My Chronic Pain?

Psychedelics Weekly – Oregon Measure 109: Approaching the Proposed Final Rules

MAPS Wraps Second Phase 3 Trial of MDMA-Assisted Therapy for PTSD

Racing Beyond Racemic: A Look at Ketamine Drug Development Ahead of...

EDITOR PICKS

‘No Prejudice, No Hype’: Florence Butlen-Ducuing on Europe’s Psychedelic Renaissance

August 2025 Psychedelic Patent Update

Unpacking FDA’s MDMA Rejection Letter and the Road Ahead for Lykos

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY